Foundayo (Orforglipron)

What is Foundayo?

Foundayo (orforglipron) is an oral GLP-1 receptor agonist, part of a class of medicines that act on the natural hormones involved in hunger and metabolism. Stimulating these pathways helps you feel fuller for longer, eat less, and improve blood sugar control. Unlike most GLP-1 drugs (such as Mounjaro, Wegovy, and Nevolat), which require injections, Foundayo has been developed as a daily pill, offering a simpler option for people seeking medical support with weight loss. This makes Foundayo an alternative to the Wegovy pill, the first oral GLP-1 medication approved in the UK. 

Though not yet licensed in the UK, it’s considered a promising upcoming treatment for obesity.

How Does Foundayo Work?

Foundayo is a GLP-1 (glucagon-like peptide-1) receptor agonist, which means it activates the same receptors in the body as the natural hormone GLP-1. GLP-1 is released in the gut after eating and plays an important role in coordinating how the body handles food and energy.

Depending on where GLP-1 binds to its receptors in the body, it increases insulin release in response to glucose, slows the rate at which food leaves your stomach (gastric emptying), and sends satiety signals (feeling full), helping to regulate appetite.

By activating the GLP-1 receptor, Foundayo may help patients:

• Feel full sooner and stay satisfied for longer
• Reduce cravings and naturally eat less
• Lose weight gradually, especially when combined with diet and exercise
• Improve blood sugar control, particularly helpful for people with type 2 diabetes

In simple terms, Foundayo works with your body’s natural appetite signals to help you eat less and lose weight sustainably.

How Long Does Foundayo Take to Work?

Weight loss is affected by a range of factors, including diet, exercise, and genetics. As such, the amount of time it takes for individuals taking Foundayo to begin losing weight (and the extent of the weight loss) varies from person to person. The prescribed medication dosage also influences the rate of weight loss.

Studies indicate that Foundayo has a mechanism of action similar to that of other GLP-1 agonists, such as Wegovy and Mounjaro. People who take these medications report reduced appetite and early signs of weight loss within 1-2 weeks. 

Foundayo Weight Loss Results 

Clinical trial results for orforglipron (the active medication in Foundayo) have been encouraging. In a 72-week Phase 3 study, participants taking the medication achieved an average weight loss of 11.2% at the highest dose (36mg), with just under 1 in 5 having a 20% or more reduction in body weight. Average weight loss ranged from 7.5% to 11.2%, depending on the dose. This is a meaningful reduction in total body weight.

A previous Phase 2 study reported weight loss ranging from 9.4% to 14.7%, depending on the dose, with participants losing between 6.9 kg and 13.0 kg by week 36 of treatment. The benefits of Foundayo went beyond weight, too, with improvements in cholesterol and blood pressure being recorded.

Further studies on Foundayo have reported improvements in long-term blood sugar levels (HbA1c).

The table below compares potential Foundayo weight loss results against other anti-obesity treatments:

While injectables may deliver slightly greater results, Foundayo’s strength lies in its convenient tablet form, offering patients an alternative to weekly injections. Though the results are promising, further trials are needed to confirm both the effectiveness and long-term safety of Foundayo.

How to Take Foundayo Tablets

If approved, Foundayo will likely be prescribed as a once-daily oral tablet. The simplicity of a daily pill could make it easier for many patients to stick with treatment compared to injections.

What to expect if prescribed:

• Take one pill each day, ideally at the same time.
• It can usually be taken with or without food. 
• Adherence is key. Missing doses may reduce its effectiveness.

Until official prescribing guidance is published, these details may change.

Foundayo Dosage Information

All GLP-1 agonist medications (including Foundayo) should be initiated with a dose-escalation regimen. This is to reduce the risk of unwanted side effects, such as nausea and gastrointestinal discomfort. If Foundayo becomes available in the UK, your prescriber will provide you with detailed dosing instructions.

The manufacturer currently provides the following advice to people taking Foundayo in the US:

• The starting dosage is 0.8 mg orally once daily. After at least 30 days at 0.8 mg, increase the dose to 2.5 mg once daily.
• After at least 30 days at 2.5 mg, increase the dose to 5.5 mg once daily.
• The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. 
• The maximum dosage of Foundayo is 17.2 mg once daily.

What if You Forget to Take Foundayo

If you forget to take a dose, take it as soon as you remember on the same day. Do not double your next scheduled dose. The manufacturer recommends that if you miss 7 consecutive days of Foundayo, you should reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions. Always take Foundayo as prescribed by your doctor. Taking more Foundayo than prescribed may increase the risk of adverse effects.

What If I Take Too Many Foundayo Pills?

Seek immediate medical attention if you take more than the prescribed number of pills (or dose) of Foundayo. Due to the prolonged amount of time that Foundayo stays in the body, you may require an extended period of medical observation if you experience adverse effects from an overdose. 

Foundayo Side Effects and Cautions

Information about potential side effects and cautions comes from clinical studies and information supplied to US consumers. More information will become available if Foundayo (orforglipron) becomes available in the UK.

Foundayo Pill Side Effects

Like other GLP-1 medicines, the most common side effects of Foundayo (orforglipron) are related to the stomach and digestion. In clinical studies, these symptoms were usually short-lived and most noticeable during dose increases. Side effects were more likely to occur at higher doses. The most common side effects reported in trials included:

• Nausea 
• Vomiting 
• Diarrhoea and constipation (often alternating, depending on how each person’s gut responded). 
• Heartburn and bloating 
• Headache 
• Dizziness
• Fatigue or feeling unusually tired 
• Abdominal pain or cramping 
• Eructation (belching) and flatulence (passing wind)
• Gastrointestinal reflux
• Hair loss

In most cases, these effects improved as patients continued treatment. Serious adverse events were rare, but some people did stop taking Foundayo because of persistent digestive problems.

Rarer potential adverse effects reported in trials included:

• Hypoglycaemia (low blood sugar)
• Acute pancreatitis
• Acute kidney injury (AKI)
• Hypotension (low blood pressure)
• Acute gallbladder disease 
• Tachycardia (raised heart rate) 
• Altered sense of taste
• Dysesthesia (abnormal burning or tingling sensation)
• Allergic reactions 
• Amylase and lipase increase in blood tests

In the UK, potential side effects are usually classified into categories (such as common, uncommon, rare, etc.) based on their likelihood of occurrence. This is to help people make a more informed decision before starting a new medication. Information on how Foundayo (orforglipron) side effects fit into these categories is not currently available. 

How Long Do Foundayo Side Effects Last?

The most common side effects with Foundayo (orforglipron) are stomach-related, like nausea or sometimes vomiting. These tend to show up in the early weeks, especially when your dose is being increased. For most people, they’re mild to moderate and pass without causing any lasting issues.

Studies found that rates were highest in the first couple of weeks, then settled down. As your body gets used to the medicine, these effects usually become less frequent and less intense.

Foundayo Warnings and Interactions 

Current information about warnings and potential interactions comes from the Patient Information Leaflet (PIL) supplied to US consumers. This information may change if Foundayo becomes available in the UK to meet our regulatory requirements.

Foundayo (orforglipron) is processed by a naturally occurring enzyme in the body called CYP3A4. Other medications can either increase (induce) or decrease (inhibit) the effectiveness of this enzyme, altering the level of Foundayo circulating in the body. The manufacturer advises caution, dose adjustment, or avoidance of Foundayo if you take certain medications that induce or inhibit CYP3A4. Your doctor can provide you with more information on which medications affect the CYP3A4 enzyme.

Foundayo delays gastric emptying and, therefore, may affect the absorption of oral medications. The manufacturer recommends that people taking oral contraceptives should switch to a non-oral form or use barrier protection (condoms) for the first 30 days of Foundayo use and for every 30 days after increases in dosage.

The manufacturer advises that the dose of other medications may need to be altered when taking Foundayo. People using Foundayo should receive more information about any changes to their medication dosage from their prescriber.

Weight loss offers no benefit to people who are pregnant, and may in fact cause foetal harm. Patients are advised to stop taking Foundayo if they become pregnant and seek urgent medical advice. Women who have the potential to become pregnant should use effective contraception while taking Foundayo. You should not take Foundayo while breastfeeding, as it may be found in the breast milk of women taking it.

Foundayo (orforglipron) should not be used by:

• Children under 18 years of age. 
• People with severe liver impairments. 
• People with an allergy to any ingredients in Foundayo (including the active drug, orforglipron)
• People with a previous history of or a family history of Medullary Thyroid Cancer (MTC) or Multiple Endocrine Neoplasia Type 2 (MEN 2).

Caution is advised in people with diabetic retinopathy and those undergoing general anaesthesia. 

Can I Get Foundayo in the UK?

Foundayo (orforglipron) is not available to purchase and cannot be prescribed by a clinician in the UK. So far, it has received FDA approval only as a prescription-only medication in the United States. You should not seek to purchase Foundayo overseas, as the efficacy and safety of medicine purchased outside of the UK (especially without medical oversight) cannot be verified.

Other GLP-1 agonist medicines, such as Wegovy injections, Wegovy pills, and Mounjaro, are available to purchase in the UK with a valid prescription. 

When Will Foundayo Be Available in the UK?

There is currently no information from the Medicines and Healthcare products Regulatory Agency (MHRA) about when Foundayo will be available in the UK. To achieve UK market authorisation, the manufacturer will need to work with the MHRA to demonstrate the product's safety and efficacy. The National Institute for Health and Care Excellence (NICE) may also review the treatment to assess its suitability for the NHS.

The Wegovy pill received UK approval roughly 6 months after it launched in the US. However, it is unclear whether the same applies to Foundayo. 

Foundayo Price: How Much Will it Cost?

Since Foundayo is not currently available in the UK, it is not possible to provide an accurate cost for those wanting to take it here. Prices may vary significantly in the UK, depending on distribution costs and other market factors, compared with its current sale price in the United States.

Pricing is usually based on the strength of the dose you need, with higher doses costing more. 

Comparing Mounjaro and Foundayo 

Mounjaro (containing the active ingredient tirzepatide) is a GLP-1 receptor agonist, similar to Foundayo, and is also used to support weight loss. Both of these medications are made by Eli Lilly. There are two main differences between Mounjaro and Foundayo. The first is that Mounjaro is administered via a once-weekly subcutaneous injection, while the second is that Mounjaro is also a GIP agonist, as well as acting on GLP-1 receptors.

Many people will have a preference between oral and injectable medications. The benefit of injecting Mounjaro is that you only have to remember to do it once a week, compared to daily tablets. However, the discomfort from injections (or a fear of needles) can be off-putting to some. Currently, only Mounjaro is available to purchase in the UK with a private prescription. 

Comparing Wegovy and Foundayo 

Wegovy (containing the active drug semaglutide) and Foundayo are both GLP-1 agonist medications used to help with weight loss. Wegovy is manufactured by Novo Nordisk and is available in the UK in both subcutaneous injection and oral pill forms. Clinical trials have demonstrated that, although there are small differences between semaglutide (Wegovy) and orforglipron (Foundayo) in tolerability and side-effect profiles, both medications are considered highly effective in supporting healthy weight loss.

Currently, only Wegovy (both injection and pill forms) is available to buy in the UK with a valid prescription. Semaglutide is also sold under the brand name Ozempic for the management of type 2 diabetes. 

Frequently Asked Questions About Foundayo Weight Loss Pills